Literature DB >> 1506629

T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation.

U Spengler1, A Möller, M C Jung, G Messer, R Zachoval, R M Hoffmann, J Eisenburg, G Paumgartner, G Riethmüller, E H Weiss.   

Abstract

Primary biliary cirrhosis (PBC) is considered an autoimmune disease characterized by destruction of small intrahepatic bile ducts by lymphocytes. Altered functions of these lymphocytes might reflect an abnormal immune response leading to tissue damage. We investigated lymphokine secretion by mitogen-stimulated T lymphocytes from the liver biopsies of patients with PBC and for comparison also peripheral blood. In PBC, diminished synthesis of lymphotoxin (TNF beta), tumor necrosis factor (TNF alpha) and interferon-gamma (IFN gamma) was found both in T-cell lines from liver tissue and in peripheral blood. The reduction was most prominent for TNF beta in early histological stages of PBC, and appeared to be a stable phenomenon when T cells were tested after long-term tissue culture. Analysis of mRNA levels indicates a possible link between reduced TNF beta production and a defect in interleukin-2 transcription. The data suggest that diminished lymphokine production in patients with PBC may play an important role in the immunopathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506629     DOI: 10.1016/0168-8278(92)90024-j

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  Primary biliary cirrhosis. Connecting molecular biology to clinical medicine.

Authors:  S Reynoso-Paz; R L Coppel; Y Nakanuma; M E Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Immunopathogenesis of primary sclerosing cholangitis.

Authors:  Joy Worthington; Sue Cullen; Roger Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 3.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

4.  Increased nitric oxide (NO) production by antigen-presenting dendritic cells is responsible for low allogeneic mixed leucocyte reaction (MLR) in primary biliary cirrhosis (PBC).

Authors:  K Yamamoto; S M Akbar; T Masumoto; M Onji
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

Review 5.  Primary biliary cirrhosis. Is (and how much of) the pathology preventible?

Authors:  Y Bar-Dayan; M E Gershwin; Y Levi; H Amital; Y Shoenfeld
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

6.  Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis.

Authors:  X Bo; U Broome; M Remberger; S Sumitran-Holgersson
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 7.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 8.  Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.

Authors:  Elena Generali; Antonio Costanzo; Carlo Mainetti; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

9.  T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function.

Authors:  D E Jones; J M Palmer; M P Leon; S J Yeaman; M F Bassendine; A G Diamond
Journal:  Gut       Date:  1997-02       Impact factor: 23.059

Review 10.  A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Authors:  Elizabeth C Goode; Simon M Rushbrook
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.